Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,504.47 86.94 0.60%
TOPIX 1,170.04 3.45 0.30%
HANG SENG 22,760.24 64.23 0.28%

Ablynx to Present at 2013 J.P. Morgan Healthcare Conference


Ablynx to Present at 2013 J.P. Morgan Healthcare Conference

GHENT, BELGIUM -- (Marketwire) -- 01/07/13 -- Ablynx (EURONEXT BRUSSELS: ABLX) today announces it will present at the 31st Annual J.P. Morgan Healthcare Conference in San Francisco, California on Thursday, 10th January 2013 at 12:00 p.m. PST (21:00 p.m. CET).

The presentation, followed by a Q&A, will be hosted by Dr Edwin Moses, CEO and Chairman of Ablynx. The presentation will provide an update on the Company's late-stage proprietary Nanobody(R) programmes, the Company's growth and partnering strategy and the outlook for the near term future.

The presentation will be webcast live and can be accessed on the day via the Ablynx website at www.ablynx.com. A replay of the webcast will be available on the Company's website for 30 days following the presentation. To ensure a timely connection, it is recommended that users register at least 10 minutes prior to the scheduled webcast.

About Ablynx Ablynx is a biopharmaceutical company engaged in the discovery and development of Nanobodies(R), a novel class of therapeutic proteins based on single-domain antibody fragments, for a range of serious human diseases, including inflammation, haematology, oncology and pulmonary disease. Today, the Company has approximately 25 programmes in the pipeline and five Nanobodies at clinical development stage. Ablynx has ongoing research collaborations and significant partnerships with major pharmaceutical companies including Boehringer Ingelheim, Merck KGaA, Novartis and Merck & Co. The Company is headquartered in Ghent, Belgium.

More information can be found on www.ablynx.com.

press release in pdf format: http://hugin.info/137912/R/1668728/541899.pdf

For more information, please contact Ablynx: Dr Edwin Moses Chairman and CEO t: +32 (0)9 262 00 07 m: +44 (0)7771 954 193 +32 (0)473 39 50 68 e: edwin.moses@ablynx.com

Marieke Vermeersch Associate Director Investor Relations t: +32 (0)9 262 00 82 m: +32 (0)479 49 06 03 e: marieke.vermeersch@ablynx.com Follow us on Twitter @AblynxABLX

M:Communications: Mary-Jane Elliott Amber Bielecka Claire Dickinson t: +44 207 920 2330 e: ablynx@mcomgroup.com

Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement